Kite, a Gilead Sciences unit, announced Tuesday that it will acquire Tmunity Therapeutics and expand its pipeline with the biotech’s next-generation CAR T therapies and technologies. Kite didn’t ...
Kite, a Gilead unit, announced Tuesday afternoon that it has hired Cindy Perettie as EVP. In the position, Perettie will oversee the CAR-T unit’s cell therapy business, effective May 30. Most recently ...
During part of Cindy Perettie’s long run at Roche, the Swiss company put her in command of one of the industry's largest oncology portfolios. A few years later, Perettie will soon find herself running ...
Gilead's Kite makes off-the-shelf play with Shoreline Biosciences CAR-NK deal worth as much as $2.3B
Gilead Sciences' Kite Pharma unit made its name developing autologous CAR-T treatments made from a patient’s own cells. Now, the subsidiary is making another big play in off-the-shelf treatments that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results